Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Long-Acting Formulations: A Promising Approach for the Treatment of Chronic Diseases

Author(s): Somaraju R. Kumar, Chetan H. Mehta and Usha Y. Nayak*

Volume 27, Issue 6, 2021

Published on: 07 July, 2020

Page: [876 - 889] Pages: 14

DOI: 10.2174/1381612826666200707122012

Price: $65

Open Access Journals Promotions 2
Abstract

Medication and patient adherence are the two main aspects of any successful treatment of chronic disease. Even though diseases and its treatment existed for several hundred years, the treatment optimization for a given patient is still a researcher question for scientists. There are differences in treatment duration, prognostic signs and symptoms between patient to patient. Hence, designing ideal formulation to suit individual patient is a challenging task. The conventional formulations like oral solids and liquids gives a partial or incomplete treatment because the patient needs to follow the daily pills for a longer time. In such cases, the long-acting formulations will have better patient compliances as drug will be released for a longer duration. Many such approaches are under the clinical investigation. The favorable pharmacokinetic and pharmacodynamic relationships, will be promising option for the treatment of chronic diseases. In this review, we have highlighted the importance of long-acting formulations in the treatment of chronic diseases and the advent of newer formulation technologies.

Keywords: Long-acting formulations, prescription adherence, chronic diseases, microspheres, implants, organogels.

« Previous
[1]
Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47(6): 555-67.
[http://dx.doi.org/10.1016/S0022-3999(99)00057-4] [PMID: 10661603]
[2]
The Global Use of Medicine 2019. Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023
[3]
Americans Visit Their Doctor 4 Times A Year. People In Japan Visit 13 Times A Year. Available at:https://www.forbes.com/sites/niallmccarthy/2014/09/04/americans-visit-their-doctor-4-times-a-year-people-in-japan-visit-13-times-a-year-infographic/#d7b4bb1e3475
[4]
Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010; 25(4): 284-90.
[http://dx.doi.org/10.1007/s11606-010-1253-9] [PMID: 20131023]
[5]
Atrium Healt Navicent Available at:https://www.navicenthealth.org/cgfm/diagnosis-and-care-of-acute-and-chronic-illness
[6]
National Council On Aging Available at:https://www.ncoa.org/blog/chronic-versus-acute-disease/
[7]
Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. Adv Drug Deliv Rev 2016; 103: 144-56.
[http://dx.doi.org/10.1016/j.addr.2016.02.003] [PMID: 26916628]
[8]
SiegelSJExtended release drug delivery strategies in psychiatry 2005.http://www.ncbi.nlm.nih.gov/pubmed/21152152
[9]
Bassett SM, Schuette SA, O’Dwyer LC, Moskowitz JT. Positive affect and medication adherence in chronic conditions: A systematic review. Health Psychol 2019; 38(11): 960-74.
[http://dx.doi.org/10.1037/hea0000778] [PMID: 31368717]
[10]
Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol 2013; 4: 91.
[http://dx.doi.org/10.3389/fphar.2013.00091] [PMID: 23898295]
[11]
Janssen Pharmaceutica NVB. 2000. Available at:https://clinicaltrials.gov/ct2/show/NCT00249223
[12]
Johnson & Johnson Pharmaceutical Research & Development LLC. A Study to assess safety and tolerabiltiy associated with a switch from oral antipsychotic medications to long-acting injectable risperidone in patients with schizophrenia 2001. Available at:https://clinicaltrials.gov/ct2/show/NCT00034775
[13]
World Health Organization Cancer . 2018. Available at:https://www.who.int/news-room/fact-sheets/detail/cancer
[14]
Global Cancer Observatory. Available at: https://gco.iarc.fr/
[15]
Monique E. The most successful cancer drugs in 2019 | Proclinical blogs 2019.Available at: https://www.proclinical.com/blogs/2019-3/the-most-successful-cancer-drugs-in-2019
[16]
Claros MP, Messa CVM, Garcia-Perdomo HA. Adherence to oral pharmacological treatment in cancer patients: Systematic review. Oncol Rev 2019; 13(1): 402.
[PMID: 31044026]
[17]
Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59(1): 56-66.
[http://dx.doi.org/10.3322/caac.20004] [PMID: 19147869]
[18]
Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86(4): 304-14.
[http://dx.doi.org/10.4065/mcp.2010.0575] [PMID: 21389250]
[19]
Shavi GV, Nayak UY, Reddy MS, et al. A novel long-acting biodegradable depot formulation of anastrozole for breast cancer therapy. Mater Sci Eng C 2017; 75: 535-44.
[http://dx.doi.org/10.1016/j.msec.2017.02.063] [PMID: 28415496]
[20]
Chang CE, Hsieh CM, Chen LC, et al. Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer. Drug Deliv 2018; 25(1): 632-43.
[http://dx.doi.org/10.1080/10717544.2018.1440444] [PMID: 29463123]
[21]
Jackman WS, Lougheed W, Marliss EB, Zinman B, Albisser AM. For insulin infusion: a miniature precision peristaltic pump and silicone rubber reservoir. Diabetes Care 1980; 3(2): 322-31.
[http://dx.doi.org/10.2337/diacare.3.2.322] [PMID: 6993148]
[22]
Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev 2007; 28(6): 625-52.
[http://dx.doi.org/10.1210/er.2007-0002] [PMID: 17785428]
[23]
WaheediMAwadAHatoumHTEnlundH2017.http://www.ncbi.nlm.nih.gov/pubmed/27878750
[24]
BroadbentE.DonkinL.StrohJ.C.Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients 2011.http://www.ncbi.nlm.nih.gov/pubmed/21270191
[http://dx.doi.org/10.2337/dc10-1779]
[25]
Ruan S, Gu Y, Liu B, et al. Long-acting release microspheres containing novel GLP-1 analog as an antidiabetic system. Mol Pharm 2018; 15(7): 2857-69.
[http://dx.doi.org/10.1021/acs.molpharmaceut.8b00344] [PMID: 29763559]
[26]
Chen Y, Luan J, Shen W, Lei K, Yu L, Ding J. Injectable and thermosensitive hydrogel containing liraglutide as a long-acting antidiabetic system. ACS Appl Mater Interfaces 2016; 8(45): 30703-13.
[http://dx.doi.org/10.1021/acsami.6b09415] [PMID: 27786459]
[27]
WHO Cardiovascular Diseases Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
[28]
LatryP.MolimardM.DedieuB.Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: A cohort study 2011.http://www.ncbi.nlm.nih.gov/pubmed/21791073
[http://dx.doi.org/10.1186/1471-2261-11-46]
[29]
RupparT.M.DelgadoJ.M.TempleJ.Medication adherence interventions for heart failure patients: A meta-analysis 2015.http://www.ncbi.nlm.nih.gov/pubmed/25669661
[http://dx.doi.org/10.1177/1474515115571213]
[30]
KruegerK.BotermannL.SchorrS.G.Griese-MammenN.LaufsU.SchulzM.Age-related medication adherence in patients with chronic heart failure: A systematic literature review Int J Cardiol 2015; 184: 728-35.http://www.ncbi.nlm.nih.gov/pubmed/25795085
[http://dx.doi.org/10.1016/j.ijcard.2015.03.042]
[31]
Efraim Y, Sarig H, Cohen Anavy N, et al. Biohybrid cardiac ECM-based hydrogels improve long term cardiac function post myocardial infarction. Acta Biomater 2017; 50: 220-33.
[http://dx.doi.org/10.1016/j.actbio.2016.12.015] [PMID: 27956366]
[32]
Wang W, Chen J, Li M, et al. Rebuilding postinfarcted cardiac functions by injecting TIIA@PDA nanoparticle-cross-linked ROS-sensitive hydrogels. ACS Appl Mater Interfaces 2019; 11(3): 2880-90.
[http://dx.doi.org/10.1021/acsami.8b20158] [PMID: 30592403]
[33]
Palmer BF, Fenves AZ. Optimizing blood pressure control in patients with chronic kidney disease. J Baylor Scott White Health 2010; 23(3)
[http://dx.doi.org/10.1080/08998280.2010.11928626]
[34]
World Kidney Day. 2019.Available at: https://www.firstpost.com/india/world-kidney-day-2019-ckd-is-6th-deadliest-disease-worldwide-causing-2-4-million-deaths-per-year-heres-how-to-reduce-risk-of-renal-ailments-6256331.html
[35]
National Kidney Foundation. About Chronic Kidney Disease: Symptoms and Causes Available at: https://www.kidney.org/atoz/content/about-chronic-kidney-disease
[36]
Kidney Disease | NIDDK Available at: https://www.niddk.nih.gov/health-information/kidney-disease
[37]
Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication safety principles and practice in CKD. Clin J Am Soc Nephrol 2018; 13(1): 1738-46.
[http://dx.doi.org/10.2215/CJN.00580118]
[38]
Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139(2): 137-47.
[http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00013] [PMID: 12859163]
[39]
WHO Chronic obstructive pulmonary disease (COPD) Available at: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)#:~:text=Chronic%20obstructive%20pulmonary%20disease%20is,leading%20to%20breathlessness%20at%20rest
[40]
Krauskopf K, Federman AD, Kale MS, et al. Chronic obstructive pulmonary disease illness and medication beliefs are associated with medication adherence. COPD 2015; 12(2): 151-64.
[http://dx.doi.org/10.3109/15412555.2014.922067]
[41]
Ross CJM, Williams BA, Low G, Vethanayagam D. Perceptions about self-management among people with severe asthma. J Asthma 2010; 47(3): 330-6.
[42]
Asthma Treatment | Asthma Treatment Guideline | ACAAI Public Website Available at: https://acaai.org/asthma/asthma-treatment
[43]
KosterESRaaijmakersJAMVijverbergSJHAsthama sypmtoms in pediatric patients: differences throughout the seasons
[44]
Levy BD, Noel PJ, Freemer MM, et al. Future research directions in asthma: An NHLBI working group report. Am J Respir Crit Care Med 2015 Dec; 1192(11): 1366-72.
[45]
Apps LD, Chantrell S, Majd S, et al. Patient perceptions of living with severe asthma: challenges to effective management. J Allergy Clin Immunol Pract 2019; 7(8): 2613-21.e1.
[http://dx.doi.org/10.1016/j.jaip.2019.04.026] [PMID: 31178414]
[46]
Devillier P, Garrigue E, D’Auzers G, Monjotin N, Similowski T, Clerc T. V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. Respir Res 2015; 16(1): 68.
[http://dx.doi.org/10.1186/s12931-015-0227-1] [PMID: 26050967]
[47]
Kaushik A, Ammerman NC, Tyagi S, et al. Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection. Antimicrob Agents Chemother 2019; 63(4): e00007-19.
[http://dx.doi.org/10.1128/AAC.00007-19] [PMID: 30745396]
[48]
BaxterAJPattonGScottKMDegenhardtLWhitefordHAGlobal epidemiology of mental disorders: What are we missing? PLoS One 2013; 8(6)e65514http://www.ncbi.nlm.nih.gov/pubmed/23826081 [cited 2020 Mar 6] Available from:
[49]
Simon GE, Stewart C, Yarborough BJ, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry 2018; 75(3): 254-60.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.4437] [PMID: 29387876]
[50]
Moreno-Kustner B, Martin C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One 2018; 13(4)e0195687
[http://dx.doi.org/10.1371/journal.pone.0195687] [PMID: 29649252]
[51]
JanssenB.GaebelW.HaerterM.KomaharadiF.LindelB.WeinmannS.Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders 2006.http://www.ncbi.nlm.nih.gov/pubmed/16710714
[http://dx.doi.org/10.1007/s00213-006-0413-4]
[52]
Rettenbacher MA, Hofer A, Eder U, et al. Compliance in schizophrenia: psychopathology, side effects, and patients’ attitudes toward the illness and medication. J Clin Psychiatry 2004; 65(9): 1211-8.
[http://dx.doi.org/10.4088/JCP.v65n0908] [PMID: 15367047]
[53]
Shah C, Patel K, Amin N, Shah C. Study of various factors affecting compliance in schizophrenia: A single center experience in India. Arch Psychiatry Psychother 2019; 3: 41-52.
[http://dx.doi.org/10.12740/APP/105489]
[54]
Ayesa-ArriolaR.Manuel Rodriguez-SanchezJ.Perez-IglesiasR.The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: A 3 year longitudinal study Psychiatry Res 2013; 30209(3): 302-8.http://www.ncbi.nlm.nih.gov/pubmed/23403293[cited 2020 Mar 6] Available from:
[55]
CoriglianoV.ComparelliA.MancinelliI.Long-acting injectable second-generation antipsychotics improve negative symptoms and suicidal ideation in recent diagnosed schizophrenia patients: a 1-year follow-up pilot study. Schizophr Res Treeatment 2018.
[56]
Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol 2016; 9(2): 169-86.
[http://dx.doi.org/10.1586/17512433.2016.1121809] [PMID: 26573020]
[57]
Barrett SE, Teller RS, Forster SP, et al. Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention. Antimicrob Agents Chemother 2018; 62(10): e01058-18.
[http://dx.doi.org/www.ncbi.nlm.nih.gov/pubmed/30012772 Available from:]
[58]
Wagner T, Furin J, Gripshover B, Jeenah Y, Jonsson G. Loss to Follow-Up among a Group of Patients with HIV and Severe Mental Illness in South Africa. World J AIDS 2014; 04(01): 74-80.
[http://dx.doi.org/10.4236/wja.2014.41009]
[59]
HammerS.M.SaagM.S.SchechterM.Treatment for adult HIV infection 2006.http://www.ncbi.nlm.nih.gov/pubmed/16905788
[http://dx.doi.org/10.1001/jama.296.7.827]
[60]
Van Der StratenA.MontgomeryE.T.MusaraP.EtimaJ.NaidooS.LabordeN.Disclosure of pharmacokinetic drug results to understand nonadherence 2015.http://www.ncbi.nlm.nih.gov/pubmed/26544581
[http://dx.doi.org/10.1097/QAD.0000000000000801]
[61]
Kovarova M, Benhabbour SR, Massud I, et al. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat Commun 2018; 9(1): 4156.
[http://dx.doi.org/10.1038/s41467-018-06490-w] [PMID: 30297889]
[62]
Goyal S, Agarwal G, Agarwal S, Karar PK. Oral sustained release tablets: an overview with a special emphasis on matrix tablet. Am J Adv Drug Deliv 2017; 05(02): 64-76.
[http://dx.doi.org/10.21767/2321-547X.1000013]
[63]
Darveshwar JagdeepD.Mule MadhavS.Birajdar ShivprasadM.Review on applications of polymers in pharmaceutical formulations Pharmatutor Available at: https://www.pharmatutor.org/articles/review-applications-polymers-pharmaceutical-formulations
[64]
Sahoo S, Kumar N, Bhattacharya C, et al. Organogels: Properties and applications in drug delivery. Des Monomers Polym 2011; 14(2): 95-108.
[http://dx.doi.org/10.1163/138577211X555721]
[65]
Sreedevi T, Ramya Devi D, Hari BN. An Emerging Era in Topical Delivery: Organogels Int J. Drug Dev Res 2012; 4(2): 35-40.
[66]
RamtekeK.H.JadhavV.B.DholeS.N.Microspheres: as carrieres used for novel drug delivery system IOSR J Pharm 2012; 244-48.www.iosrphr.org [cited 2020 Mar 6] Available from:
[67]
Sree Giri Prasad B, Gupta VRM, Devanna N, Jayasurya K. Microspheres as drug delivery system - A Review. J Glob Trends Pharm Sci 2014; 5(3): 1961-72.
[68]
Stewart SA, Dominguez-Robles J, Donnelly RF, Larraneta E. Implantable polymeric drug delivery devices: Classification, manufacture, materials, and clinical applications. Polymers (Basel) 2018; 10(12): 1379.
[http://dx.doi.org/10.3390/polym10121379] [PMID: 30961303]
[69]
Mandhar P, Joshi G. Development of sustained release drug delivery system: a review. Mandhar Joshi ASIAN PACIFIC J Heal Sci 2015; 2(1): 179-85.
[http://dx.doi.org/10.21276/apjhs.2015.2.1.31]
[70]
Zalte HD, Saudagar RB. Review on sustained release matrix tablet. Int J Pharma Bio Sci 2019; 3(4): 17-29.
[71]
Sampath KumarK.P.BhowmikD.SrivastavaS.PaswanS.DuttaA.S.The Pharma Innovation Sustained Release Drug Delivery System Potential Available at: https://www.researchgate.net/publication/285176110_THE_PHAMA_INNOVATION_Sustained_Release_Drug_Delivery_System_Potential
[72]
Federica C, Alice M, Saliha M, et al. Injection molded capsules for colon delivery combining time-controlled and enzyme-triggered approaches. Int J Mol Sci 2020; 21(6): 1917.
[http://dx.doi.org/10.3390/ijms21061917] [PMID: 32168895]
[73]
Sankar R, Jain SK. Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: A mechanistic study. Drug Des Devel Ther 2013; 7: 1455-69.
[74]
Jiang P, Chaparro FJ, Cuddington CT, et al. Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration. J Control Release 2020; 320: 442-56.
[http://dx.doi.org/10.1016/j.jconrel.2020.01.036] [PMID: 31981659]
[75]
Liu D, Yu S, Zhu Z, et al. Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation. Int J Pharm 2014; 475(1-2): 496-503.
[http://dx.doi.org/10.1016/j.ijpharm.2014.09.008] [PMID: 25219321]
[76]
Yin L, Qin C, Chen K, et al. Gastro-floating tablets of cephalexin: preparation and in vitro/in vivo evaluation. Int J Pharm 2013; 452(1-2): 241-8.
[http://dx.doi.org/10.1016/j.ijpharm.2013.05.011] [PMID: 23680730]
[77]
Xu L, Luo Y, Feng J, Xu M, Tao X, He H, et al. Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability. Int J Pharm 2012; 17422(1-2): 9-16.
[78]
TranP.H.L.TranT.T.D.PiaoZ.Z.Van VoT.ParkJ.B.LimJ.Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion 2013.http://www.ncbi.nlm.nih.gov/pubmed/23612354
[http://dx.doi.org/10.1016/j.ijpharm.2013.04.022]
[79]
Auvinen VV, Virtanen J, Merivaara A, et al. Modulating sustained drug release from nanocellulose hydrogel by adjusting the inner geometry of implantable capsules. J Drug Deliv Sci Technol 2020.57101625
[http://dx.doi.org/10.1016/j.jddst.2020.101625]
[80]
Kim JY, Lee SH, Park CW, et al. Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets. Drug Des Devel Ther 2015; 9: 695-706.
[PMID: 25678774]
[81]
Nayak AK, Pal D, Hasnain SM. Development, optimization and in vitro-in vivo evaluation of pioglitazone- loaded jackfruit seed starch-alginate beads. Curr Drug Deliv 2013; 10(5): 608-19.
[http://dx.doi.org/10.2174/1567201811310050012] [PMID: 23360248]
[82]
Sulpiride – DrugBank. Available at: . https://www.drugbank.ca/drugs/DB00391
[83]
Bhattacharya SS, Banerjee S, Chowdhury P, Ghosh A, Hegde RR, Mondal R. Tranexamic acid loaded gellan gum-based polymeric microbeads for controlled release: in vitro and in vivo assessment. Colloids Surf B Biointerfaces 2013; 112: 483-91.
[http://dx.doi.org/10.1016/j.colsurfb.2013.07.054] [PMID: 24183265]
[84]
Alam N, Beg S, Rizwan M, et al. Mucoadhesive elementary osmotic pump tablets of trimetazidine for controlled drug delivery and reduced variability in oral bioavailability. Drug Dev Ind Pharm 2015; 141(4): 692-702.
[http://dx.doi.org/10.3109/03639045.2014.900076]
[85]
Mamatha T, Anupama K, Abdul HM, Kanwal QH. Formulation and evaluation of extended-release tablets of an antidepres-sant drug Venlafaxine HCl. Int J Res Pharm Sci 2020; 239(4): 1146-53.
[86]
Prajapati ST, Patel AN, Patel CN. Formulation and evaluation of controlled-release tablet of zolpidem tartrate by melt granulation technique. ISRN Pharm 2011; •••2011208394
[http://dx.doi.org/10.5402/2011/208394] [PMID: 22389845]
[87]
Midha K. Microspheres: a recent update. Int J Recent Sci Res 2015; 85860-1.http://www.recentscientific.com/microspheres-recent-update Available at:
[88]
Saini S, Kumar S, Choudhary M. Nitesh, Budhwar V. Microspheres as controlled drug delivery system: an updated review. Int J Pharm Sci Res 2018; 9(5): 1760-8.
[89]
Sun F, Yu C, Liu X, et al. Butyl stearate prolongs the drug release period of isoperidone’loaded poly (lactic-co-glycolic acid) microspheres: In vitro and in vivo investigation. Mol Med Rep 2019; 19(3): 1595-602.
[PMID: 30592277]
[90]
Bansode SD, Kasture VS, Pawar SS, Kasture SB. Formulation and evaluation of telmisartan microspheres by emulsion solvent evaporation technique. J Appl Pharm Sci 2012; 2(10): 113-6.
[91]
Patel KS, Patel MB. Preparation and evaluation of chitosan microspheres containing nicorandil. Int J Pharm Investig 2014; 4(1): 32-7.
[http://dx.doi.org/10.4103/2230-973X.127738] [PMID: 24678460]
[92]
Blasi P. Poly(lactic acid)/poly(lactic-co-glycolic acid)-based microparticles: an overview. J Pharm Investig 2019; 49(4): 337-46.
[http://dx.doi.org/10.1007/s40005-019-00453-z]
[93]
Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 2011; 3(3): 1377-97.
[94]
Park CW, Lee HJ, Oh DW, Kang JH, Han CS, Kim DW. Preparation and in vitro/in vivo evaluation of PLGA microspheres containing norquetiapine for long-acting injection. Drug Des Devel Ther 2018; 12: 711-9.
[http://dx.doi.org/10.2147/DDDT.S151437] [PMID: 29670329]
[95]
Benhabbour SR, Kovarova M, Jones C, et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat Commun 2019; 2010(1): 1-2.
[http://dx.doi.org/10.1038/s41467-019-12141-5]
[96]
Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm 2011; 415(1-2): 34-52.
[http://dx.doi.org/10.1016/j.ijpharm.2011.05.049] [PMID: 21640806]
[97]
Kokina M, Shamtsyan M, Georgescu C, Mironescu M, Nedovic V. Essential oil/alginate microcapsules; obtaining and applying. Immunopathol Persa 2019; 105(1)
[98]
Kim D, Han TH, Hong S-C, et al. PLGA microspheres with alginate-coated large pores for the formulation of an injectable depot of donepezil hydrochloride. Pharmaceutics 2020; 112(4): 311.
[99]
Zhang C, Wang A, Wang H, et al. Entecavir-loaded poly (lactic-co-glycolic acid) microspheres for long-term therapy of chronic hepatitis-B: Preparation and in vitro and in vivo evaluation. Int J Pharm 2019; 560: 27-34.
[http://dx.doi.org/10.1016/j.ijpharm.2019.01.052] [PMID: 30711615]
[100]
Wang Y, Sun T, Zhang Y, et al. Exenatide loaded PLGA microspheres for long-acting antidiabetic therapy: Preparation, characterization, pharmacokinetics and pharmacodynamics. RSC Advances 2016; 6(44): 37452-62.
[http://dx.doi.org/10.1039/C6RA02994A]
[101]
Wang P, Zhuo X, Chu W, Tang X. Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity. Int J Pharm 2017; 528(1-2): 62-75.
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.069] [PMID: 28579543]
[102]
Lee D-S, Kang DW, Choi G-W, Choi H-G, Cho H-Y. Development of level a in vitro-vivo correlation for electrosprayed microspheres containing leuprolide: physicochemical, pharmacokinetic, and pharmacodynamic evaluation. Pharmaceutics 2020; 212(1): 36.
[103]
Nanaki S, Viziridou A, Zamboulis A, Kostoglou M, Papageorgiou GZ, Bikiaris DN. New biodegradable poly(l-lactide)-block-poly(propylene adipate) copolymer microparticles for long-acting injectables of naltrexone drug. Polymers (Basel) 2020; 12(4)E852
[http://dx.doi.org/10.3390/polym12040852] [PMID: 32272700]
[104]
Pathak P, Paliwal S. Preparation and characterization of intramuscular PLGA based microsphere. J Drug Deliv Ther 2019; 9(5): 127-30.
[http://dx.doi.org/10.22270/jddt.v9i5.3631]
[105]
Nanaki S, Tseklima M, Terzopoulou Z, et al. Use of mesoporous cellular foam (MCF) in preparation of polymeric microspheres for long acting injectable release formulations of paliperidone antipsychotic drug. Eur J Pharm Biopharm 2017; 117: 77-90.
[http://dx.doi.org/10.1016/j.ejpb.2017.03.016] [PMID: 28389342]
[106]
Jafarifar E, Hajialyani M, Akbari M, Rahimi M, Shokoohinia Y, Fattahi A. Preparation of a reproducible long-acting formulation of risperidone-loaded PLGA microspheres using microfluidic method. Pharm Dev Technol 2017; 22(6): 836-43.
[http://dx.doi.org/10.1080/10837450.2016.1221426] [PMID: 27494230]
[107]
Nanaki S, Barmpalexis P, Papakonstantinou Z, Christodoulou E, Kostoglou M, Bikiaris DN. Preparation of new risperidone depot microspheres based on novel biocompatible poly(alkylene adipate) polyesters as long-acting injectable formulations. J Pharm Sci 2018; 107(11): 2891-901.
[http://dx.doi.org/10.1016/j.xphs.2018.07.029] [PMID: 30096352]
[108]
Nanaki S, Barmpalexis P, Iatrou A, Christodoulou E, Kostoglou M, Bikiaris D. Risperidone Controlled Release Microspheres Based on Poly(Lactic Acid)-Poly(Propylene Adipate) Novel Polymer Blends Appropriate for Long Acting Injectable Formulations. Pharmaceutics 2018; 1310(3): 130.
[109]
Zhang C, Wu L, Tao A, Bera H, Tang X, Cun D, et al. Formulation and in vitro characterization of long-acting PLGA injectable microspheres encapsulating a peptide analog of LHRH. J Mater Sci Technol 2020; •••: 29.
[110]
Jose J, Gopalan K. Organogels: A versatile drug delivery tool in pharmaceuticals. Res J Pharm Technol 2018; 11(3): 1242.
[http://dx.doi.org/10.5958/0974-360X.2018.00231.7]
[111]
TarunG.AjayB.BhawanaK.SunilK.RaviJ.BihaniS.G.L.Organogels: advanced and novel drug delivery system. Rese J Pharm 2011; Vol. 2.
[112]
Singh VK, Ramesh S, Pal K, Anis A, Pradhan DK, Pramanik K. Olive oil based novel thermo-reversible emulsion hydrogels for controlled delivery applications. J Mater Sci Mater Med 2014; 25(3): 703-21.
[http://dx.doi.org/10.1007/s10856-013-5112-1] [PMID: 24327110]
[113]
Rehman K, Zulfakar MH. Recent advances in gel technologies for topical and transdermal drug delivery. Drug Dev Ind Pharm 2014; 40(4): 433-40.
[http://dx.doi.org/10.3109/03639045.2013.828219] [PMID: 23937582]
[114]
Esposito CL, Tardif V, Sarrazin M, Kirilov P, Roullin VG. Preparation and characterization of 12-HSA-based organogels as injectable implants for the controlled delivery of hydrophilic and lipophilic therapeutic agents. Mater Sci Eng C 2020; 114110999
[115]
SurjyanarayanMSnigdhaMSKrutikaS
[116]
Liu H, Wang Y, Han F, Yao H, Li S. Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of Cyclosporin A in vitro and dermal pharmacokinetics in vivo. J Pharm Sci 2007; 96(11): 3000-9.
[http://dx.doi.org/10.1002/jps.20898] [PMID: 17705159]
[117]
Ibrahim M, Hafez S. Organogels, hydrogels and bigels as transdermal delivery systems for diltiazem hydrochloride. Asian J Pharm Sci 2013; 8(1): 48-57.
[118]
Dai M, Bai L, Zhang H, et al. A novel flunarizine hydrochloride-loaded organogel for intraocular drug delivery in situ: Design, physicochemical characteristics and inspection. Int J Pharm 2020.576119027
[http://dx.doi.org/10.1016/j.ijpharm.2020.119027] [PMID: 31953090]
[119]
Wei Z, Huang Q. Developing organogel-based Pickering emulsions with improved freeze-thaw stability and hesperidin bioaccessibility. Food Hydrocoll 2019; 93: 68-77.
[http://dx.doi.org/10.1016/j.foodhyd.2019.01.050]
[120]
Vigato AA, Querobino SM, de Faria NC, et al. Synthesis and characterization of nanostructured lipid-poloxamer organogels for enhanced skin local anesthesia. Eur J Pharm Sci 2019; 128: 270-8.
[http://dx.doi.org/10.1016/j.ejps.2018.12.009] [PMID: 30553060]
[121]
Madan JR, Sagar BK, Chellappan D, et al. Development and evaluation of transdermal organogels. Antiinflamm Antiallergy Agents Med Chem 2013; 12(3): 246-52.
[122]
AgrawalV.GuptaV.RamtekeS.TrivediP.Preparation and evaluation of tubular micelles of pluronic lecithin organogel for transdermal delivery of sumatriptan 2010.http://www.ncbi.nlm.nih.gov/pubmed/21128126
[http://dx.doi.org/10.1208/s12249-010-9540-7]
[123]
Charoensumran P, Ajiro H. Controlled release of testosterone by polymer-polymer interaction enriched organogel as a novel transdermal drug delivery system: Effect of limonene/PG and carbon-chain length on drug permeability. React Funct Polym 2020.148104461
[http://dx.doi.org/10.1016/j.reactfunctpolym.2019.104461]
[124]
Querobino SM, de Faria NC, Vigato AA, et al. Sodium alginate in oil-poloxamer organogels for intravaginal drug delivery: Influence on structural parameters, drug release mechanisms, cytotoxicity and in vitro antifungal activity. Mater Sci Eng C 2019; 99: 1350-61.
[http://dx.doi.org/10.1016/j.msec.2019.02.036] [PMID: 30889669]
[125]
RautS.Y.SuruseP.B.ShivhareU.D.BhusariK.P.Development and evaluation of non-ionic surfactant based organogels for transdermal delivery of zidovudine Available at: https://www.researchgate.net/publication/228809192
[126]
Stewart SA, Dominguez-Robles J, Donnelly RF, Larraneta E. Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications. Polymers (Basel) 2018; 10(12): 1379.
[127]
Choktanasiri W, Rojanasakul A. Buserelin Acetate Implants in the Treatment of Pain in Endometriosis. J Med Assoc Thai 2001; 84(5): 656-60.
[128]
Westphal M, Hilt DC, Bortey E, et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003; 15(2): 79-88.
[129]
Mathur V, Mudnaik R, Barde L, Roy A, Shivhare U, Bhusari K. Formulation and evaluation of controlled release antibiotic biodegradable implants for post operative site delivery. Acta Pharm 2010; 60(1): 111-7.
[http://dx.doi.org/10.2478/v10007-010-0005-z] [PMID: 20228045]
[130]
Pehlivan SB, Yavuz B, Calamak S, et al. Preparation and in vitro/in vivo evaluation of cyclosporin A-loaded nanodecorated ocular implants for subconjunctival application. J Pharm Sci 2015; 104(5): 1709-20.
[http://dx.doi.org/10.1002/jps.24385] [PMID: 25716582]
[131]
Baum MM, Butkyavichene I, Gilman J, et al. An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci 2012; 101(8): 2833-43.
[http://dx.doi.org/10.1002/jps.23208] [PMID: 22619076]
[132]
Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001; 75(5): 865-70.
[http://dx.doi.org/10.1016/S0015-0282(01)01689-2] [PMID: 11334895]
[133]
Wong IB, Teoh SC, Yeoh AE, Lingam G. Sustained-release ganciclovir implant as prophylaxis for cytomegalovirus retinitis in a child undergoing bone marrow transplantation. Eye (Lond) 2013; 27(7): 890-1.
[134]
Goldspiel BR, Kohler DR. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer. DICP 1991; 25(7-8): 796-804.
[http://dx.doi.org/10.1177/106002809102500716] [PMID: 1835221]
[135]
All Wales Medicines Strategy Group (AWMSG) - leuprorelin acetate (Prostap SR DCS/Prostap 3 DCS)
[136]
Lee S, Choy YB. Implantable devices for sustained, intravesical drug delivery. Int Neurourol J 2016; 20(2): 101.
[http://dx.doi.org/10.5213/inj.1632664.332]
[137]
Barrett SE, Teller RS, Forster SP, et al. Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention. Antimicrob Agents Chemother 2018; 62(10): 1058-76.
[138]
Mastiholimath V, Dandagi P, Gadad A, Patil M, Manvi F, Chandur V. Formulation and evaluation of ornidazole dental implants for periodontitis. Indian J Pharm Sci 2006; 68(1): 68-71.
[http://dx.doi.org/10.4103/0250-474X.22967]
[139]
Hiremath JG, Khamar NS, Palavalli SG, Rudani CG, Aitha R, Mura P. Paclitaxel loaded carrier based biodegradable polymeric implants: Preparation and in vitro characterization. Saudi Pharm J 2013; 21(1): 85-91.
[http://dx.doi.org/10.1016/j.jsps.2011.12.002] [PMID: 23960822]
[140]
Navitha A, Jogala S, Krishnamohan C, Aukunuru J. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies. J Adv Pharm Technol Res 2014; 5(2): 84.
[141]
Dammerman R, Kim S, Adera M, Schwarz A. Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia. Clin Pharmacol Drug Dev 2018; 7(3): 298-310.
[http://dx.doi.org/10.1002/cpdd.428] [PMID: 29420868]
[142]
Anselmo A, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release 2014; 190: 15-28.
[143]
Wang A, Liu Y, Liang R, et al. Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson’s disease and its evolution study. Saudi Pharm J 2016; 24(3): 363-70.
[http://dx.doi.org/10.1016/j.jsps.2016.04.022] [PMID: 27275128]
[144]
Wei G, Jin L, Xu L, Liu Y, Lu W. Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants. Int J Pharm 2010; 398(1-2): 123-9.
[http://dx.doi.org/10.1016/j.ijpharm.2010.07.036] [PMID: 20674730]
[145]
Isaac M, Holvey C. Transdermal patches: The emerging mode of drug delivery system in psychiatry. Ther Adv Psychopharmacol 2012; 2(6): 255-63.
[146]
PastoreMNKaliaYNHorstmannMRobertsMSTransdermal patches: History, development and pharmacology. Brit J Pharmacol; 172.
[147]
Nagasamy Venkatesh D. Shrestha Niroj, Sharma Jeevan. Transdermal drug delivery system: An overview. Int J Res Pharm Sci 2012; 3(2): 234-41.
[148]
KailashVPratibhaCMahavirGAshwiniPMangeshK.Transdermal Delivery: A Recent Trend in Treatment of Chronic Diseases. J Pharm Res - BioMedRx 2013; 1(5): 473-9.
[149]
MedlinePlus. Clonidine Transdermal Patch: MedlinePlus Drug Information. Available at: https://medlineplus.gov/druginfo/meds/a608049.html#why
[150]
MedlinePlus. Granisetron Transdermal Patch: MedlinePlus Drug Information. Available at: https://medlineplus.gov/druginfo/meds/a609015.html
[151]
MedlinePlus. Rivastigmine Transdermal Patch: MedlinePlus Drug Information. Available at: https://medlineplus.gov/druginfo/meds/a607078.html
[152]
MedlinePlus. Rotigotine Transdermal Patch: MedlinePlus Drug Information. Available at: https://medlineplus.gov/druginfo/meds/a607059.html
[153]
NIH US National Library of Medicine. Available at: MedlinePlus. Rotigotine Transdermal Patch: MedlinePlus Drug Information. Available at: https://clinicaltrials.gov/

Rights & Permissions Print Cite
Article Metrics
52
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy